Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort

Background: Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control. Methods: We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation). Results: Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40). Conclusions: In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-18
DOI
https://doi.org/10.3390/antibiotics15111150
Primary Topic
Orthopedic Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort

Bianca Catania, Andrea De Vito, Fabrizio Pulvirenti, Chiara Iaria et al.
3 links
Antibiotics
Orthopedic Infections and Treatments
article

Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort

Bianca Catania, Andrea De Vito, Fabrizio Pulvirenti, Chiara Iaria, Alessandro Geremia, Nicholas Geremia, Laura Santoro, Emmanuele Venanzi Rullo, Eugenia Pistarà, Antonio Albanese, Giuseppe Pipitone, Giuseppe Nunnari, Carmelo Iacobello, Giordano Madeddu, Andrea Marıno, Bruno Santi Cacopardo, Alessandro Franzò, Barbara Bellocchi, Rosa Manuele, Serena Spampinato, A Buzzi, Paolo Italia
article en

Abstract

Background: Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control. Methods: We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation). Results: Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40). Conclusions: In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.

AntibioticsVol. 15(11)
University of Messina (IT), University of Sassari (IT), University of Catania (IT), Ospedale Garibaldi (IT), Ospedale Cannizzaro (IT), Ospedale dell' Angelo (IT), Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT), Ospedale Civile di Venezia (IT), Ospedale Civile di Vittorio Veneto (IT), Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
Good health and well-being
Orthopedic Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon